Accuphase revenue 370 million yuan in the first half gross profit of 258 million yuan marie digby

Accuphase revenue 370 million yuan in the first half gross profit of 258 million yuan a thousand thousand shares hot column capital flows on stock diagnosis the latest rating simulated trading client sina finance App: Live on-line blogger to tutor Sina Hong Kong APP: real time market exclusive reference stocks also worth the investment? What’s the problem? Where is the future of the way out? Sina launched the "Hong Kong Hong Kong stocks as well as unattractive" discussion, with a rational and constructive attitude, welcome attention to Hong Kong stocks, concern of the capital market, Hong Kong stocks together for suggestions, seek the Hong Kong stock market tomorrow. Please to hkstock_biz@sina. August 29th, Accuphase (06896) announced the first half of 2016 annual report (Unaudited), the indicators are to maintain sustained growth, the income grew 6.3% to 370 million 600 thousand yuan, gross profit grew 2.3% to 258 million 400 thousand yuan. During the reporting period, Jin Sangzi tablet revenue growth to 326 million 700 thousand yuan, up slightly compared to the same period of 2015; Jin Sangzi throat treasure products revenue growth to 20 million 900 thousand yuan, compared with 2015 growth of 19.4% over the same period; herb drinks and Ginkgo Biloba Leaves Extract Tablets and other income increased to 23 million yuan, compared with 2015 growth of 411.1% over the same period. At present, Accuphase established a comprehensive distribution network, through a combination of online and offline, covering all the provinces, autonomous regions and municipalities directly under the central government. At the same time, expanding overseas markets. Such as the introduction of a large and powerful distribution network and Internet channels in North America, the United States agents, with more than 600 thousand retail pharmacies at all levels of the famous India pharmaceutical companies to achieve cooperation intentions. At present, Accuphase group products have been involved in a number of overseas markets including the United States, Canada, EU, Australia, Southeast Asia and the Middle East. As a leading manufacturer of lozenges, since the 1994 launch of Accuphase tablet, with marketing ability and strong distribution network, become known to every family of well-known brands. Report of the third party authority Euromonitor International, Jin Sangzi Runhou tablet products (including Jin Sangzi and Jin Sangzi throat throat treasure Series) occupy the largest market share in China, about 25.8%. At the beginning of this year, and entered the field of food beverage and the introduction of Accuphase herb beverage caused widespread concern in the market and consumers. Future Ltd will continue to seek to consolidate its leading position in Runhou tablet market, continues to expand its Chinese in medicine and food market. Most importantly, the company will strive to enhance production capacity, expand product mix and enhance R & D capabilities, strengthen its food and other drug business and promote synergies between different product segments. Promote brand awareness through effective targeted marketing, and continue to expand its distribution network, improve infrastructure and use its existing distribution network to promote different products. The industry believes that, as the Chinese Runhou tablet enterprises, Accuphase’s golden throat tablets and golden throat products by the market and consumers. The introduction of new products of herbal beverages相关的主题文章: